| Ticker Details |
Prime Medicine Inc
The investment seeks to provide long-term total return.
Under normal market conditions, the fund will seek to achieve its investment objective by investing at least 80% of its net assets (including investment borrowings) in U.S. and non-U.S. exchange-traded real estate securities, which includes real estate investment trusts ("REITs"), real estate operating companies ("REOCs") and common stocks or depositary receipts of companies primarily engaged in the real estate industry (collectively, "Real Estate Securities"). It is non-diversified.
|
| IPO Date: |
October 20, 2022 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$590.27M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.29 | 4.09%
|
| Avg Daily Range (30 D): |
$0.15 | 3.90%
|
| Avg Daily Range (90 D): |
$0.19 | 4.49%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.32M |
| Avg Daily Volume (30 D): |
2.58M |
| Avg Daily Volume (90 D): |
3.12M |
| Trade Size |
| Avg Trade Size (Sh.): |
145 |
| Avg Trade Size (Sh.) (30 D): |
160 |
| Avg Trade Size (Sh.) (90 D): |
164 |
| Institutional Trades |
| Total Institutional Trades: |
296 |
| Avg Institutional Trade: |
$1.76M |
| Avg Institutional Trade (30 D): |
$.89M |
| Avg Institutional Trade (90 D): |
$1.45M |
| Avg Institutional Trade Volume: |
.28M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.13M |
| Avg Closing Trade (30 D): |
$.82M |
| Avg Closing Trade (90 D): |
$1.47M |
| Avg Closing Volume: |
339.04K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-.32
|
$-.41
|
$-.4
|
|
Diluted EPS
|
$-.32
|
$-.41
|
$-.4
|
|
Revenue
|
$1.23M
|
$1.12M
|
$1.45M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$-50.58M
|
$-52.59M
|
$-51.89M
|
|
Operating Income / Loss
|
$-53.97M
|
$-53.38M
|
$-52.39M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$17.59M
|
$-38.44M
|
$-90.6M
|
|
PE Ratio
|
|
|
|
|
|
|
